#USA #Orlando #Orna Therapeutics #Autoimmune Diseases #CAR therapy

Orna Therapeutics to Showcase Breakthrough CAR Programs at ASH Annual Meeting

Orna Therapeutics, headquartered in Watertown, Massachusetts, is set to make waves at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. This biotechnology company is at the forefront of developing innovative immune cell engineering techniques designed to tackle the challenges posed by autoimmune diseases and cancer. During the conference, Orna will present pivotal oral and poster sessions focusing on its in vivo CAR (Chimeric Antigen Receptor) therapy initiatives, specifically targeting B-cell driven autoimmune conditions.

Key Presentations and Insights

Oral Presentation: In Vivo pan CAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases

• - Speaker: Dr. Isin Dalkilic-Liddle, VP Discovery Sciences, Orna Therapeutics
• - Date/Time: Saturday, December 6, 2025, from 9:45 AM to 10:00 AM ET
• - Session Name: CAR-T Cell Therapies - Basic and Translational In vivo CAR-T cell platforms and resistance mechanisms
• - Location: Orlando Convention Center, Sunburst Room (W340)

Dr. Dalkilic-Liddle will share new, revealing data from non-human primate (NHP) studies tied to Orna's pioneering CD19 and BCMA panCAR programs. The findings are expected to emphasize the exceptional performance of Orna’s CAR platform therapy in NHP trials, setting a new standard in the clinical landscape.

Poster Presentation: In Vivo pan CAR Therapy Utilizing Circular RNA for Treatment of Multiple Myeloma

• - Speaker: Dr. Rebecca Silver, Principal Scientist, Orna Therapeutics
• - Date/Time: Sunday, December 7, 2025, from 6:00 PM to 8:00 PM ET
• - Session Name: CAR-T Cell Therapies - Basic and Translational Poster II
• - Location: Orlando Convention Center, West Halls B3-B4

Dr. Silver will present findings emphasizing the versatility and efficacy of Orna's RNA platform in targeting multiple myeloma, shedding light on innovative ways to confront this challenging hematological malignancy.

Focus on Innovative Technology

Orna's technology leverages oRNA (engineered circular RNA) and utilizes lipid nanoparticle (LNP) delivery systems to create a new wave of therapeutic solutions. The data presented at ASH will underscore the ability of Orna's oRNA panCAR therapeutics to achieve profound and prolonged B-cell depletion in clinical applications, highlighting their potential impact across a variety of B-cell related autoimmune diseases.

Joseph Bolen, Ph.D., the CEO of Orna Therapeutics, expressed enthusiasm about the data to be shared, stating, “We are excited to share new data at ASH from our NHP studies for our CD19 and BCMA panCAR programs. Our data continues to demonstrate the best-in-class nature of our in vivo CAR platform.” Additionally, he announced that the company had completed its pre-clinical package for the anti-CD19 program and plans to submit the Clinical Trial Application shortly.

About Orna Therapeutics

Founded with the vision of expanding the therapeutic possibilities of RNA medicine, Orna Therapeutics aims to deliver innovative circular RNA solutions capable of addressing a myriad of health challenges. Their oRNA constructs promise simpler production processes and enhanced efficacy compared to traditional mRNA therapies, potentially revolutionizing patient care in the realm of genetic medicine. To find out more about Orna Therapeutics and their pioneering research, visit www.ornatx.com and follow them on social media platforms such as X and LinkedIn.

With their presentations at the ASH conference, Orna Therapeutics is not only setting the stage for advancements in autoimmune disease therapy but is also paving the way for the next generation of RNA-based treatments that could provide solutions for patients afflicted by these challenging conditions.